Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

(You can read the full research report on Procter & Gamble here >>>) Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-50% vs.

Pharma trade lobby EFPIA, whose members include European pharma giants Bayer, Novartis and Novo Nordisk, said it had called on EU President Ursula von der Leyen to push for "rapid and radical ...

The investment, which is one of the largest in Brazil’s history according to Novo Nordisk, will see the pharma company’s Montes Claros facility upgraded with new aseptic production processes ...

As India grapples with a mounting obesity crisis — with over 250 million individuals affected and health costs projected to reach 1.57 per cent of GDP by 2030 — Danish pharmaceutical company ...